New Treatment For Asthma, COPD Flare-Ups: Single Dose Of Existing Antibody Injection May Cut Hospitalizations

Participants treated with benralizumab showed improved respiratory symptoms, including reduced cough, wheezing, breathlessness, and sputum, after 28 days. (Credit: Image by karkenimages.com on Freepik)

For millions of people struggling with asthma or COPD, a higher dose of an existing antibody injection could be a total game changer, a recent trial results reveal.

According to the study conducted by a research team from the University of Oxford and Kings College London, a single injection of a monoclonal antibody, benralizumab, could be more effective than standard steroid tablets during asthma or COPD flare-ups.